WHAT'S MISSING FROM THIS PICTURE?

Deciding whether Medicare will start covering a new medical technology or other service is not supposed to take cost effectiveness into consideration — at least not publicly. Clinical effectiveness, medical necessity and patient safety are the only factors that are allowed to be discussed.

This directive was evident during a recent Medicare Evidence Development & Coverage Advisory Committee hearing in Baltimore to determine if the program should cover certain positron emission tomography scans that oculd offer an early diagnosis of Alzheimer's disease.

A word cloud constructed by *American Medical News* using the official transcript from the hearing — demonstrating the frequency with which certain words were used — does not contain "cost" or any other terms related to how much the program would be expected to pay for the technology in relation to its value for patients.


amyloid
Alzheimer's
dementia
disease
AD
PET
cognitive
diagnosis
patients
think
imaging
research
people
evidence
confidence
scan
clinical
data
studies
outcomes
important
brain
positive
just
know
Medicare
population
symptoms
impairment
negative
really
see
memory
syndrome
question
time
preclinical
years
stage
MCI
changes
early
prodromal
highly
patient
actually
even
function
older
may
vote
normal
helpful
intermediate
Number
comment
confident
information
trials
well
also
workup
study
talking
like
answer
atypical
months
quality
new
genetic
need
present
dysfunction
atrophy
past
life
death
used
scans
conclusions
specificity
someone
age
beta
things
much
going
percent
panel
care
since
means
issue
family
Now
sure
clinic
back
huge
comes
part
lot
step
change
use
number
discuss
deposition
certainly
anti-amyloid
take
problem
mean
high
start
perhaps
many
clinically
voting
voted
individuals
thought
impact
way
field
management
mild
status
gaps
discussion
health
beneficiary
now
Question
development
questions
phase
testing
coverage
diagnostic
presence
treatment
good
work
lack
Medicare
Medicare
Medicare